Cytokinetics, Incorporated
CYTK
Rang in Aktien
#2283
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Aktienkurs
$62.83
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$8.73B
Veränderung (1 Tag)
-1.75%
Veränderung (1 Jahr)
14.73%
Land
US
Handel Cytokinetics, Incorporated (CYTK)
Kategorie
Healthcare
Kursverlauf für Cytokinetics, Incorporated (CYTK)
Höchster Schlusskurs: $62.96 am 2026-10-01
Niedrigster Schlusskurs: $97.08 am 2004-04-01
Niedrigster Schlusskurs: $97.08 am 2004-04-01
Kursverlauf der Aktie von Cytokinetics, Incorporated von 2004 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 8.70% |
| 2025 | 28.55% |
| 2024 | 11.95% |
| 2023 | 4.76% |
| 2022 | 4.97% |
| 2021 | 101.81% |
| 2020 | 97.15% |
| 2019 | 42.08% |
| 2018 | -14.22% |
| 2017 | -29.65% |
| 2016 | 4.66% |
| 2015 | 114.65% |
| 2014 | -19.66% |
| 2013 | 59.81% |
| 2012 | -32.39% |
| 2011 | -55.97% |
| 2010 | -23.56% |
| 2009 | 26.62% |
| 2008 | -55.25% |
| 2007 | -26.58% |
| 2006 | -3.72% |
| 2005 | -20.38% |
| 2004 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.08 | -4.30% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
